<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01194063</url>
  </required_header>
  <id_info>
    <org_study_id>107954</org_study_id>
    <nct_id>NCT01194063</nct_id>
  </id_info>
  <brief_title>Use of Omegaven Fish Oil Emulsion for Parenteral Nutrition Associated Liver Disease in Infants and Children</brief_title>
  <official_title>Use of Omegaven for Parenteral Nutrition Associated Liver Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kapiolani Medical Center For Women &amp; Children</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kapiolani Medical Center For Women &amp; Children</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Use of a fish oil emulsion to decrease liver disease due to long term intravenous nutrition.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Unlike conventional intravenous fat emulsions, Omegaven™ is comprised solely of fish oils
      containing primarily omega-3 fatty acids. Animal studies have shown that IV fat emulsions
      such as fish oil that are high in eicosapentaenic and docosahexaenoic acids reduce impairment
      of bile flow as seen in cholestasis caused by conventional fat emulsions. It is thought that
      by administering Omegaven™ in place of conventional phytosterol/soybean fat emulsions,
      cholestasis may be prevented or reversed, and patients will be able to be maintained on
      adequate PN for growth until they are able to ingest adequate nutrition enterally. Ongoing
      studies are addressing safety and efficacy of Omegaven™ in the pediatric population. In this
      trial, infants and children with parenteral nutrition associated liver disease will receive
      Omegaven™ as compassionate use to potentially prevent progression of disease. Safety and
      efficacy are monitored.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Anticipated">August 2025</completion_date>
  <primary_completion_date type="Anticipated">August 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>improving cholestasis</measure>
    <time_frame>One month, 2 months, 3 months after starting omegaven and 1 month after completing treatment</time_frame>
    <description>decline in serum direct bilirubin levels below 2 cm on 2 serial measures</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>improving liver function tests</measure>
    <time_frame>1 year</time_frame>
    <description>includes ALT, AST, GGT, and triglycerides</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Cholestasis</condition>
  <arm_group>
    <arm_group_label>Omegaven</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration of intravenous Omega-3 fish oil lipid emulsion 1 g/kg continuous infusion over 12-24 hrs</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omega-3 fish oil lipid emulsion</intervention_name>
    <description>daily intravenous administration of Omegaven fish oil emulsion</description>
    <arm_group_label>Omegaven</arm_group_label>
    <other_name>Omegaven</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  direct bilirubin &gt; 2 mg/dl x2 consecutive

          -  parenteral nutrition dependent, expected to continue for at least another 30 days from
             the first day

          -  patient must have utilized standard therapies to prevent the progression of liver
             disease

        Exclusion Criteria:

          -  other primary cause of liver disease not parenteral nutrition-associated

          -  weight &lt;3 kg

          -  infant or child enrolled in other clinical trial involving an investigational agent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lynn M Iwamoto, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kapiolani Medical Center For Women &amp; Children</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lynn M Iwamoto, MD</last_name>
    <phone>808-983-8670</phone>
    <email>lynni@kapiolani.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Charles Neal, MD PhD</last_name>
    <phone>808-983-8670</phone>
    <email>cneal@kapiolani.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Kapiolani Medical Center for Women and Children</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96826</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Lynn M Iwamoto, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Charles R Neal, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sidney Johnson, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Lee SI, Valim C, Johnston P, Le HD, Meisel J, Arsenault DA, Gura KM, Puder M. Impact of fish oil-based lipid emulsion on serum triglyceride, bilirubin, and albumin levels in children with parenteral nutrition-associated liver disease. Pediatr Res. 2009 Dec;66(6):698-703. doi: 10.1203/PDR.0b013e3181bbdf2b.</citation>
    <PMID>19687773</PMID>
  </reference>
  <reference>
    <citation>de Meijer VE, Le HD, Meisel JA, Gura KM, Puder M. Parenteral fish oil as monotherapy prevents essential fatty acid deficiency in parenteral nutrition-dependent patients. J Pediatr Gastroenterol Nutr. 2010 Feb;50(2):212-8. doi: 10.1097/MPG.0b013e3181bbf51e.</citation>
    <PMID>20038849</PMID>
  </reference>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 17, 2010</study_first_submitted>
  <study_first_submitted_qc>September 1, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 2, 2010</study_first_posted>
  <last_update_submitted>September 21, 2017</last_update_submitted>
  <last_update_submitted_qc>September 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kapiolani Medical Center For Women &amp; Children</investigator_affiliation>
    <investigator_full_name>Lynn M. Iwamoto</investigator_full_name>
    <investigator_title>MD, Associate Professor of Pediatrics</investigator_title>
  </responsible_party>
  <keyword>short bowel syndrome</keyword>
  <keyword>parenteral nutrition associated liver disease</keyword>
  <keyword>pediatric</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Cholestasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

